Development of the VirtualTAVR system for diagnostics and preventative strategies

Information

  • Research Project
  • 8906931
  • ApplicationId
    8906931
  • Core Project Number
    R43HL124798
  • Full Project Number
    5R43HL124798-02
  • Serial Number
    124798
  • FOA Number
    PA-10-122
  • Sub Project Id
  • Project Start Date
    8/15/2014 - 10 years ago
  • Project End Date
    1/31/2017 - 7 years ago
  • Program Officer Name
    EVANS, FRANK
  • Budget Start Date
    2/1/2016 - 8 years ago
  • Budget End Date
    1/31/2017 - 7 years ago
  • Fiscal Year
    2016
  • Support Year
    02
  • Suffix
  • Award Notice Date
    12/31/2015 - 8 years ago
Organizations

Development of the VirtualTAVR system for diagnostics and preventative strategies

DESCRIPTION (provided by applicant): Since the first procedure in 2002, there has been an explosive growth in transcatheter aortic valve replacement (TAVR). Up to date, more than 50,000 TAVR had been performed worldwide. Despite the increased global experience with TAVR, severe adverse events associated with TAVR have been extensively documented, including annulus rupture, coronary occlusion, paravalvular leak (PVL), pacemaker implantation, vascular complications and stroke. Currently, there is no effective method to pre-operatively predict and prevent these adverse events. To assist clinicians with diagnostic and preventative strategies to prevent these clinical adverse events, we propose to develop a novel virtual TAVR system (VirtualTAVR) that can display 3D aortic vasculature for TAVR planning, coupled with a workflow report of essential TAVR-associated parameters such as annulus diameter, cross sectional area, as well as distribution and degree of calcification. The unique and most important feature of the system is that it can virtually simulate the deployment of a TAV device into an individual patient aortic root and evaluate the tissue-device biomechanical interaction. The simulation output will be guidelines for appropriate access route selection, proper TAV sizing and positioning and desired TAV expansion force inside a patient's aortic root to avoid the abovementioned adverse events. The heart valve industry has long been expecting the $2 billion surgical market to be transformed into a $12 billion TAV market, but to date this has been prevented by poor TAV clinical trial performance. The virtual TAVR system offers a way to facilitate this transformation by improving patient outcomes. More importantly, its contribution to patient healthcare, i.e., improving quality of life in patients, could be immeasurable.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R43
  • Administering IC
    HL
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    193415
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
    NHLBI:193415\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    DURA, LLC
  • Organization Department
  • Organization DUNS
    078526313
  • Organization City
    STORRS
  • Organization State
    CT
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    062694213
  • Organization District
    UNITED STATES